8-K: Senseonics Announces Preliminary 2024 Results, Eversense 365 Launch Update, and Cancels Special Meeting

Senseonics reported preliminary 2024 financial results, highlighted the successful launch of Eversense 365, and cancelled a special meeting regarding a proposed reverse stock split.

Summary

• Senseonics announced preliminary unaudited revenue of approximately $8.3 million for the fourth quarter of 2024 and $22.5 million for the full year 2024.
• The company's operating expenses and cash utilization for both the fourth quarter and full year 2024 were consistent with previous guidance.
• Senseonics expects to have approximately $74.9 million in cash, cash equivalents, and restricted cash as of December 31, 2024.
• The patient base increased by 56% in 2024 compared to 2023, reaching approximately 6,000 global patients.
• The company has cancelled a special meeting of stockholders that was scheduled for January 10, 2025, to vote on a proposed reverse stock split.
• The decision to cancel the meeting was made after assessing the pricing implications of a reverse split and considering shareholder feedback.
• Senseonics received FDA approval for the Eversense 365 Continuous Glucose Monitoring system and launched it with commercial partner Ascensia.
• The company saw strong early launch performance indicators for Eversense 365, including a doubling of direct-to-consumer leads in Q4 compared to Q3, and the highest monthly new patient shipments in December.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth in patient base and successful product launch, but the cancellation of the reverse stock split and the preliminary nature of the financial results introduce some uncertainty.

Positives

• The company experienced a 56% increase in its patient base in 2024.
• The launch of Eversense 365 has shown strong early performance indicators.
• New patient shipments reached a record high in December 2024.
• Patient referrals from physicians have significantly increased since the launch of Eversense 365.
• The company's cash position is expected to be approximately $74.9 million at the end of 2024.

Negatives

• The preliminary financial results are unaudited and subject to change.
• The company cancelled a special meeting to consider a reverse stock split, which may indicate concerns about the stock price.

Risks

• The preliminary financial information is subject to change and may differ from the audited results.
• The company's future performance is subject to various factors, including the execution of Ascensia's business unit, regulatory approvals, and the economic environment.
• There are uncertainties inherent in the development and commercialization of new technology and solutions.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects positive revenue growth in 2025 compared to 2024, and plans to provide detailed financial guidance in conjunction with its full fiscal year 2024 results. They also expect to provide updates on pump-connectivity, additional health care systems and their ex-US launch over the course of the year.

Management Comments

• 2024 was a tremendous year for Senseonics, achieving our long-term goal of commercializing the Eversense 365 product, providing people with diabetes a convenient and accurate solution for monitoring blood glucose for an entire year with a single sensor.
• Patient and provider leads, conversion rates, and interest from health systems have all increased significantly since the U.S. 365 launch, culminating in the highest number of monthly new patient shipments in December 2024, and we expect to see those numbers continue to accelerate in 2025.

Industry Context

The announcement highlights Senseonics' progress in the competitive continuous glucose monitoring market, particularly with the launch of its long-term implantable Eversense 365 system. The partnership with Ascensia and the focus on health system collaborations are also key trends in the medical device industry.

Comparison to Industry Standards

• Senseonics' 56% patient base growth is a strong indicator of market adoption, though specific comparisons to competitors like Dexcom and Abbott require further analysis of their respective growth rates.
• The launch of Eversense 365, a 365-day implantable CGM, differentiates Senseonics from competitors offering shorter-term solutions, such as Dexcom's G7 and Abbott's Freestyle Libre 3.
• The reported revenue of $22.5 million for 2024 is relatively small compared to the larger players in the CGM market, indicating that Senseonics is still in a growth phase.

Stakeholder Impact

• Shareholders may be impacted by the cancellation of the reverse stock split and the preliminary nature of the financial results.
• Patients will benefit from the availability of the Eversense 365 system.
• Employees may be impacted by the company's growth and future plans.
• Ascensia, as a commercial partner, will be impacted by the success of the Eversense 365 launch.

Next Steps

• The company plans to report its full fourth quarter and fiscal year 2024 financial results later this quarter.
• Senseonics plans to provide financial guidance for 2025 in conjunction with its full fiscal year 2024 financial results.
• The company expects to provide updates on pump-connectivity, additional health care systems and their ex-US launch over the course of the year.

Key Dates

Keywords

Eversense 365, Continuous Glucose Monitoring, CGM, Diabetes, Revenue, Financial Results, Reverse Stock Split, Ascensia, Patient Base, FDA Approval